The cranberry extract produced using a Biosfered Srl proprietary technology is first titrated with the DMAC method to obtain the total amount of PACs and subsequently is analyzed by liquid chromatography coupled to mass spectrometry (HPLC-ESI-MS/MS) for the assessment of the content of the PAC A (and the possible presence of PAC B).

Oximacro-FL

Oximacro-FL

The liquid formulation allows the use of Oximacro in all fluid preparations. The high concentration of PAC A of the liquid extract allows reduction of the final product volume, while maintaining a high concentration of bioactive PAC A.

Extractive technique

Extractive technique

The extractive technique at low temperatures developed by Biosfered S.r.l. allows to obtain also in the dried extract an enrichment of the bioactive PAC A fraction.
The product is perfectly soluble in water and does not contain insoluble residues (e.g., maltodextrins, cell walls, etc..).

UTI and dosage of PACs

UTI and dosage of PACs

In humans, administration of a cranberry dried extract standardized in PACs (DMAC) at doses containing 72 mg of PAC per day, divided in two doses of 36 mg in the morning and evening, offers protection against bacterial adhesion and virulence in the urinary tract (Howell et al. BMC Infect. Dis. 2010, 10:94).